177Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians

Ting Bu; Lulu Zhang; Fei Yu; Xiaochen Yao; Wenyu Wu; Pengjun Zhang; Liang Shi; Shiming Zang; Qingle Meng; Yudan Ni; Guoqiang Shao; Xuefeng Qiu; Shuyue Ai; Ruipeng Jia; Hongqian Guo; Feng Wang

doi:10.3389/fonc.2022.835956

¹⁷⁷Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians

Front Oncol. 2022 Mar 24:12:835956. doi: 10.3389/fonc.2022.835956. eCollection 2022.

Authors

Ting Bu¹, Lulu Zhang¹, Fei Yu¹, Xiaochen Yao¹, Wenyu Wu¹, Pengjun Zhang¹, Liang Shi¹, Shiming Zang¹, Qingle Meng¹, Yudan Ni¹, Guoqiang Shao¹, Xuefeng Qiu², Shuyue Ai¹, Ruipeng Jia³, Hongqian Guo², Feng Wang¹

Affiliations

¹ Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
² Department of Urology, Nanjing Drum Hospital, Nanjing University, Nanjing, China.
³ Department of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.

Abstract

Purpose: There is increasing evidence for convincing efficacy and safety of ¹⁷⁷Lu-labled prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (PRLT) for metastatic castration-resistant prostate cancer (mCRPC). However, data are not available regarding the feasibility of ¹⁷⁷Lu-labled PSMA-targeted RLT in East Asians. The present study summarized the first experience with ¹⁷⁷Lu-PSMA-I&T therapy for mCRPC in China.

Methods: Forty consecutive patients with mCRPC were enrolled from December 2019 to September 2021. Eligible patients received ¹⁷⁷Lu-PSMA-I&T RLT at intervals of 8-12 weeks. Toxicity was assessed based on standardized physicians' reports and the Common Toxicity Criteria for Adverse Events criteria. Response to PRLT was evaluated according to the changes of prostate specific antigen (PSA) response and imaging response. Quality of life (QOL), Karnofsky performance status (KPS) and pain (visual analogue scale, VAS) were also evaluated. The impacts of baseline parameters on the therapeutic effects were explored by univariate and multivariate logistic regression analyses.

Results: All patients underwent a total of 86 cycles of ¹⁷⁷Lu-PSMA-I&T (range: 1-5 cycles) with dosages of 3.70-14.43GBq per cycle, with a median of 8 months followed up. Six patients (15%) developed mild reversible xerostomia during follow-up, and 28 patients (70%) experienced grade 1-4 bone marrow dysfunction. Changes in PSA were assessed after therapy, accompanied by the partial response (PR) in 25 patients (62.5%), the stable disease (SD) in 5 patients (12.5%), and the progressive disease (PD) in 10 patients (25%), respectively. QOL, KPS (%) and VAS scores were improved significantly due to treatment (P<0.05). Overweight and elevated AST, ALP, and LDH were associated with poor outcomes.

Conclusions: ¹⁷⁷Lu-PSMA-I&T achieves the favourable response and well tolerance in mCRPC, which associates with not only PSA decline but also with tumor remission including lymphadenopathy and bone metastasis. We also find that patients with overweight and high AST, ALP, and LDH should be cautious to undergo the PRLT. Large-cohort studies are warranted to confirm the initial findings and elucidate the survival benefit of the treatment.

Keywords: 177Lu; metastatic castration-resistant prostate cancer (mCRPC); prostate cancer; prostate-specific membrane antigen (PSMA); radioligand therapy (RLT).